Human PDX Breast Cancer Organoid – Invasive Ductal Carcinoma is a three-dimensional patient-derived xenograft (PDX) tumor model cultured from invasive ductal breast carcinoma tissue. Engineered from tumor-resident stem-like cells, this organoid preserves the pathological, genetic, and phenotypic characteristics of the original tumor, including receptor status (e.g., ER, PR, HER2). It maintains tumor heterogeneity, supports long-term expansion, and recapitulates the architecture and treatment response patterns of clinical breast cancers, offering a physiologically relevant platform for translational oncology.
Embedded 3D Culture
All test negative for mycoplasma, bacteria, yeast, and fungi.
For research use only. Human breast cancer organoid is an advanced tool for preclinical research, including drug screening, hormonal therapy evaluation, and molecular profiling. It is particularly suited for breast cancer or receptor-defined subtypes, allowing for precise assessment of drug efficacy and resistance. The organoid enables personalized therapy development by modeling patient-specific tumor behavior and supports co-culture systems for immunotherapy and tumor microenvironment studies. Its PDX origin adds high clinical relevance for the development of next-generation targeted therapies.
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.
Whether you're exploring disease mechanisms or screening novel therapeutics, OgCelix is your trusted partner.
Let's build the future of translational research together.